Comparing the current results to its competitors, Bone Biologics reported Revenue decrease in the 2 quarter 2026 year on year by 0 %, despite the revenue increase by the most of its competitors of 9.12 %, recorded in the same quarter.
Bone Biologics Corporation, despite income growth by most of its competitors recorded a net loss, despite income increase by most of its competitors of 58.48 %
Bone Biologics's Comment on Competition and Industry Peers
Bone Biologics operates in the orthobiologic and orthopedic industries, which are characterized by rapid technological advancements and a strong focus on intellectual property. The company faces significant competition from established orthopedic firms with greater resources, including Medtronic, Stryker, Globus Medical, and DePuy-Synthes. Competitors may develop and commercialize products that offer improved safety, effectiveness, convenience, or cost advantages, and may obtain regulatory approvals, such as from the FDA, more quickly, potentially securing market positions ahead of Bone Biologics.
Procept Biorobotics Corporation follows a business model focused on developing medical robotics solutions for urology procedures. Their flagship product, the AquaBeam System, utilizes waterjet technology to perform minimally invasive surgeries for patients with benign prostatic hyperplasia. The company aims to improve patient outcomes and reduce healthcare costs by providing an innovative and efficient alternative to traditional surgical methods.
Orthofix Medical Inc is a company that focuses on developing and selling medical devices and orthopedic solutions to healthcare providers and patients.
Monogram Orthopaedics Inc. operates on a specialized business model focused on developing and manufacturing innovative orthopedic medical devices. With a strong emphasis on research and development, they design cutting-edge solutions to address various musculoskeletal conditions. The company collaborates with healthcare professionals to test and refine their products, ensuring their efficacy and safety for patients.
Medtronic Plc operates a global business model centered on the development and distribution of advanced medical technologies across four key segments: Cardiac and Vascular, Minimally Invasive Therapies, Restorative Therapies, and Diabetes. The company emphasizes innovation and collaboration with healthcare providers to enhance patient outcomes and drive efficiency within healthcare systems.
Sources:
Bone Biologics Corporation’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Bone Biologics Corporation versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
